Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

January 31, 2017

Study Completion Date

June 30, 2017

Conditions
Solid TumorsNon-Small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Panobinostat, Cisplatin, Pemetrexed

"Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.~Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1."

Trial Locations (2)

48202

Henry Ford Health System, Detroit

95817

University of California Davis Cancer Center, Sacramento

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of California, Davis

OTHER